Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
32
datasets available to search
ShareScore release 0.9.0
Dataset results
32 results for “Candesartan cilexetil”
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
ClinicalTrials.gov study NCT00108706. IPD Sharing: Not stated. Countries: 1. Publications: 3.
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
ClinicalTrials.gov study NCT00227318. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
ClinicalTrials.gov study NCT05920005. IPD Sharing: NO. Countries: 1. Publications: 1.
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
ClinicalTrials.gov study NCT00242346. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Figure 7 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 7 The in vitro release profile of Candesartan cilexetil-loaded nanosuspensions and Candesartan cilexetil powder at A. Dissolution medium phosphate buffer (pH 6.8) and B. Dissolution medium HCl buffer (pH 1.2). Data are represented as mean ± standard deviation of three independent experiments.
Figure 8 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 8 Particle size and EE % analysis of the Candesartan cilexetil-loaded nanosuspensions. A. Particle size and B.EE % over three months at 32 °C, 25 °C and 4 °C. Data are represented as mean ± standard deviation of three independent experiments. * p-value > 0.05.
Figure 4 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 4 The AFM images of the Candesartan cilexetil-loaded nanosuspensions. A. 3D AFM image of candesartan cilexetil-loaded nanosuspensions; B. 2D AFM image of candesartan cilexetil-loaded nanosuspensions.
Figure 6 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 6 The DSC thermogram of A. pure candesartan cilexetil; B. Candesartan cilexetil-loaded nanosuspensions; C. Candesartan cilexetil-free nanosuspensions; D.PVP K-30; E. HPMS E5; F.PXM 188.
Figure 5 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 5 FTIR spectrum of A. Pure candesartan cilexetil compound; B.PVP K-30 polymer; C.HPMC E5 polymer; D.PXM 188 polymer; E. Candesartan cilexetil-free nanosuspensions; and F. Candesartan cilexetil-loaded nanosuspensions.
Figure 3 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 3 Response surface 3D plots showing the effect of independent variables on the dependent variables via (a) particle size, (b) PDI, (c) EE%, and (d) DL% by Design-Expert® software.
Figure 1 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 1 Calibration curve of candesartan cilexetil in HCl buffer (pH 1.2). Candesartan cilexetil was dissolved in HCl buffer (pH 1.2) at a concentration of 5, 10, 20, 30 and 50 µg.ml-1, and the U.V. absorbance at λmax 254 nm was gained. Data are represented as mean ± standard deviation of 3 independent experiments.
Figure 2 from: Al-Edresi S, Albo Hamrah K, Al-Shaibani A (2024) Formulation and validation of Candesartan cilexetil-loaded nanosuspension to enhance solubility. Pharmacia 71: 1-13. https://doi.org/10.3897/pharmacia.71.e114943
Figure 2 Calibration curve of candesartan cilexetil in phosphate buffer (pH 6.8). Candesartan cilexetil was dissolved in phosphate buffer (pH 6.8) at a concentration of 5, 10, 20, 30 and 50 µg.ml-1, and the U.V. absorbance at λmax 254 nm was gained. Data are represented as mean ± standard deviation of 3 independent experiments.
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
ClinicalTrials.gov study NCT00634309. IPD Sharing: Not stated. Countries: 0. Publications: 4.
Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24
ClinicalTrials.gov study NCT00679484. IPD Sharing: YES. Countries: 3. Publications: 0.
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
ClinicalTrials.gov study NCT02211638. IPD Sharing: NO. Countries: 1. Publications: 0.
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hyper
ClinicalTrials.gov study NCT01788358. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
ClinicalTrials.gov study NCT01976572. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
ClinicalTrials.gov study NCT02016183. IPD Sharing: NO. Countries: 1. Publications: 0.
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
ClinicalTrials.gov study NCT00634712. IPD Sharing: Not stated. Countries: 0. Publications: 8.
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
ClinicalTrials.gov study NCT00573742. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.